Prieto-Pérez, R
Solano-López, G
Cabaleiro, T
Román, M
Ochoa, D
Talegón, M
Baniandrés, O
López-Estebaranz, J L
de la Cueva, P
Daudén, E
Abad-Santos, F
Article History
Received: 24 July 2015
Revised: 15 December 2015
Accepted: 2 May 2016
First Online: 27 September 2016
Competing interests
: F Abad-Santos has been a consultant or investigator in clinical trials sponsored by the following pharmaceutical companies: Abbott, Alter, Chemo, Farmalíder, Ferrer, GlaxoSmithKline, Gilead, Janssen-Cilag, Kern, Normon, Novartis, Servier, Teva and Zambon. E Daudén has potential conflicts of interest (advisory board member, consultant, grants, research support, participation in clinical trials, honoraria for speaking and research support) with the following pharmaceutical companies: AbbVie (Abbott), Amgen, Janssen-Cilag, Leo Pharma, Novartis, Pfizer, MSD and Celgene. P de la Cueva has conflicts of interest (advisory board member, consultant, grants, research support, participation in clinical trials, honoraria for speaking and/or research support) with the following pharmaceutical companies: AbbVie (Abbott), Astellas, Janssen-Cilag, Leo Pharma, Novartis, Pfizer, MSD, Gebro, Isdin and Lilly. JL López-Estebaranz has conflicts of interest (advisory board member, speaker or participation in clinical trials) with AbbVie, Amgen, Pfizer, MSD, Janssen-Cilag, Lilly and Celgene. O Baniandrés has conflicts of interest (participation in clinical trials and honoraria for speaking) with the following pharmaceutical companies: AbbVie (Abbott), Janssen-Cilag, Leo Pharma, Pfizer and MSD.